retatrutide 2025 trial results Today's TRIUMPH-4 are a clear signal: the next generation of incretin medications will be more powerful than anything we've seen before. is showing nearly 30% body-weight reduction in clinical trials Retatrutide is the most significant

Its activity in diabetic study populations approaches outcomes observed in individuals with obesity without diabetes, indicating its potential as a next-generation subject of investigation

Nausea is the primary side effect and is dose-dependent

Sivaramakrishnan, T

I recommend them to all of my friends

Preclinical work also points to applications in reproductive health (e.g., PCOS-related fertility improvements) and oncology, where observational studies link GLP-1 use to lower risks of obesity-related cancers

Neeraj Agarwal: So both classes of drugs look like can have profound effect on the metabolic pathways in various ways